持田製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4534/E00947 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2020/04/10 | 日証協 | 110,752株 | +28.83% | 70,031株 | +144.19% | 192,420株 | +5.19% | 68,761株 | -12.1% |
2020/04/03 | 日証協 | 85,967株 | -29.92% | 28,679株 | -52.75% | 182,929株 | -19.58% | 78,227株 | +12.57% |
2020/03/27 | 日証協 | 122,667株 | +26.41% | 60,700株 | +15.07% | 227,470株 | -2.35% | 69,492株 | +31.12% |
2020/03/19 | 日証協 | 97,039株 | -16.07% | 52,749株 | -26.51% | 232,934株 | +0.65% | 53,000株 | +24.98% |
2020/03/13 | 日証協 | 115,622株 | -5.22% | 71,781株 | -20.59% | 231,441株 | -9.69% | 42,408株 | -26.98% |
2020/03/06 | 日証協 | 121,984株 | -2.13% | 90,390株 | +2.97% | 256,283株 | +22.02% | 58,079株 | +10.12% |
2020/02/28 | 日証協 | 124,638株 | -10.52% | 87,787株 | -9.04% | 210,041株 | +6.09% | 52,742株 | +61.79% |
2020/02/21 | 日証協 | 139,298株 | +13.71% | 96,512株 | +14.59% | 197,980株 | +12.18% | 32,600株 | -24.19% |
2020/02/14 | 日証協 | 122,505株 | +17.86% | 84,224株 | +70.29% | 176,480株 | +5.07% | 43,004株 | -39.92% |
2020/02/07 | 日証協 | 103,937株 | -10.74% | 49,458株 | +197.22% | 167,970株 | +5.23% | 71,583株 | +181.98% |
2020/01/31 | 日証協 | 116,437株 | -11.14% | 16,640株 | -77.93% | 159,624株 | +2.02% | 25,386株 | -58.9% |
2020/01/24 | 日証協 | 131,030株 | +14.01% | 75,408株 | +80.82% | 156,467株 | -4.8% | 61,770株 | +17.97% |
2020/01/17 | 日証協 | 114,930株 | +7.18% | 41,703株 | +0.56% | 164,351株 | +1.88% | 52,362株 | -9.1% |
2020/01/10 | 日証協 | 107,230株 | -10.22% | 41,472株 | +702.17% | 161,321株 | +6.91% | 57,602株 | +638.49% |
2019/12/30 | 日証協 | 119,430株 | +3.02% | 5,170株 | -92.32% | 150,896株 | +0.27% | 7,800株 | -79.07% |
2019/12/27 | 日証協 | 115,930株 | +0.43% | 67,361株 | -23.66% | 150,496株 | +5.51% | 37,270株 | -39.86% |
2019/12/20 | 日証協 | 115,434株 | -16.79% | 88,242株 | -5.81% | 142,632株 | -8.29% | 61,968株 | -20.64% |
2019/12/13 | 日証協 | 138,721株 | -6.67% | 93,686株 | -18.23% | 155,519株 | +2.31% | 78,081株 | +63.48% |
2019/12/06 | 日証協 | 148,634株 | +17.73% | 114,568株 | +527.43% | 152,002株 | +5.3% | 47,763株 | +72.74% |
※株式分割は考慮していませんのでご注意ください。
Page Top